BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND FOXO3, FKHRL1, 2309, ENSG00000118689, MGC31925, MGC12739, FOXO2, FOXO3A, O43524, AF6q21, FKHRL1P2, DKFZp781A0677 AND Treatment
17 results:

  • 1. Nuclear MAST4 Suppresses foxo3 through Interaction with AKT3 and Induces Chemoresistance in pancreatic Ductal Carcinoma.
    Fujiwara-Tani R; Sasaki T; Bhawal UK; Mori S; Ogata R; Sasaki R; Ikemoto A; Kishi S; Fujii K; Ohmori H; Sho M; Kuniyasu H
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612866
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
    Uddin MH; Al-Hallak MN; Khan HY; Aboukameel A; Li Y; Bannoura SF; Dyson G; Kim S; Mzannar Y; Azar I; Odisho T; Mohamed A; Landesman Y; Kim S; Beydoun R; Mohammad RM; Philip PA; Shields AF; Azmi AS
    Clin Transl Med; 2023 Dec; 13(12):e1513. PubMed ID: 38131168
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prolyl isomerase Pin1 promotes autophagy and cancer cell viability through activating foxo3 signalling.
    Long J; Wang J; Dong Y; Yang J; Xie G; Tong Y
    Cell Signal; 2024 Jan; 113():110940. PubMed ID: 38084839
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. LINC00472 suppressed by ZEB1 regulates the miR-23a-3p/foxo3/BID axis to inhibit the progression of pancreatic cancer.
    Bi C; Wang G
    J Cell Mol Med; 2021 Sep; 25(17):8312-8328. PubMed ID: 34363438
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. pancreatic cancer induces muscle wasting by promoting the release of pancreatic adenocarcinoma upregulated factor.
    Yoo W; Choi H; Son YH; Lee J; Jo S; Jung D; Kim YJ; Koh SS; Yang YR; Kwon ES; Lee KP; Noh KH; Kim KW; Ko Y; Jun E; Kim SC; Kim S
    Exp Mol Med; 2021 Mar; 53(3):432-445. PubMed ID: 33731895
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Linc00261 inhibits metastasis and the WNT signaling pathway of pancreatic cancer by regulating a miR‑552‑5p/foxo3 axis.
    Chen T; Lei S; Zeng Z; Zhang J; Xue Y; Sun Y; Lan J; Xu S; Mao D; Guo B
    Oncol Rep; 2020 Mar; 43(3):930-942. PubMed ID: 32020223
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival.
    Giordano F; Naimo GD; Nigro A; Romeo F; Paolì A; De Amicis F; Vivacqua A; Morelli C; Mauro L; Panno ML
    Drug Des Devel Ther; 2019; 13():4265-4274. PubMed ID: 31908413
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Dracorhodin perchlorate induces apoptosis and G2/M cell cycle arrest in human esophageal squamous cell carcinoma through inhibition of the JAK2/STAT3 and AKT/foxo3a pathways.
    Lu Z; Lu C; Li C; Jiao Y; Li Y; Zhang G
    Mol Med Rep; 2019 Sep; 20(3):2091-2100. PubMed ID: 31322237
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/foxo3 signaling pathway.
    Yao Y; Zhou L; Liao W; Chen H; Du Z; Shao C; Wang P; Ding K
    Carbohydr Polym; 2019 Jan; 204():111-123. PubMed ID: 30366522
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Cytotoxic Effects of Valproic Acid on Neuroendocrine Tumour Cells.
    Arvidsson Y; Johanson V; Pfragner R; Wängberg B; Nilsson O
    Neuroendocrinology; 2016; 103(5):578-91. PubMed ID: 26505883
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via foxo3a activation.
    Zhou Y; Liang C; Xue F; Chen W; Zhi X; Feng X; Bai X; Liang T
    Oncotarget; 2015 Apr; 6(12):10350-65. PubMed ID: 25871400
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress.
    Zhang JG; Hong DF; Zhang CW; Sun XD; Wang ZF; Shi Y; Liu JW; Shen GL; Zhang YB; Cheng J; Wang CY; Zhao G
    Cancer Sci; 2014 Apr; 105(4):445-54. PubMed ID: 24484175
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer.
    Pathania D; Sechi M; Palomba M; Sanna V; Berrettini F; Sias A; Taheri L; Neamati N
    Biochim Biophys Acta; 2014 Jan; 1840(1):332-43. PubMed ID: 23954204
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of fkhrl1/foxo3a and neuropilin.
    Shankar S; Marsh L; Srivastava RK
    Mol Cell Biochem; 2013 Jan; 372(1-2):83-94. PubMed ID: 22971992
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway.
    Shin-Kang S; Ramsauer VP; Lightner J; Chakraborty K; Stone W; Campbell S; Reddy SA; Krishnan K
    Free Radic Biol Med; 2011 Sep; 51(6):1164-74. PubMed ID: 21723941
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells.
    Zhao G; Cui J; Zhang JG; Qin Q; Chen Q; Yin T; Deng SC; Liu Y; Liu L; Wang B; Tian K; Wang GB; Wang CY
    Gene Ther; 2011 Sep; 18(9):920-8. PubMed ID: 21677689
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway.
    Boreddy SR; Pramanik KC; Srivastava SK
    Clin Cancer Res; 2011 Apr; 17(7):1784-95. PubMed ID: 21350002
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.